lemzoparlimab,azacitidine
abbvie,i-mab
['azacitidine,(-oral azaci),(-azacitidine oral)', 'lemzoparlimab', ' i-mab ']
at #esmo22 today i-mab announced encouraging data from its phase 2 clinical trial (nct04202003) of lemzoparlimab in combination with azacitidine (aza) in patients with newly diagnosed higher risk myelodysplastic syndrome (hr-mds). details: 
Global biotech company focused on novel and highly differentiated biologics for immuno-oncology to bring transformational medicines to patients worldwide